| abstract |
Pharmaceutical compositions comprising compounds of the formula: R2C{CH2O(CH2)nCO[NR3CHR(CH¿2?)mCO]qNOHR?1}¿3, wherein R is hydrogen, alkyl optionally substituted by OR?5, SR5, NR5R6, COR6, COOR6, CONR5R6¿, -NHC(NR?5R6)=NR7¿, aryl, aralkyl or heteroaryl; R?1, R2 and R3¿ are independently selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, COOR?4, CONHR4¿ and CONR4R4; R2 may additionally be alkyl susbstituted by alkoxy, alkenyloxy or by a group -O-(CH¿2?)p-COOX or -O-(CH2)p-CONHX, wherein p is an integer from 1 to 10 and X is alkyl, aralkyl, aryl or heteroaryl; R?4, R5 and R6¿ are hydrogen, alkyl, aralkyl, aryl or heteroaryl; n is 1 or 2; m is 0, 1 or 2 and q is 0 or 1, and when m is 0, the moiety -NR3CHR- may be a pyrrolidine ring, or a pharmaceutically acceptable salt thereof, are useful for removal of iron (III) from mammalian cells and iron (III)-dependent organisms and for treatment of iron (III) overload and disorders caused by iron (III)-dependent pathogenic organisms, such as Plasmodium falciparum that causes malaria. |